Fibrosarcoma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma – Drugs In Development, 2021, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 7, 6 and 8 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Advenchen Laboratories LLC

Alphamab Oncology

AntiCancer Inc

Apollomics Inc

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Bicycle Therapeutics Plc

BioMed Valley Discoveries Inc

Cellestia Biotech AG

F. Hoffmann-La Roche Ltd

Intezyne Inc

Lytix Biopharma AS

Mediolanum farmaceutici SpA

Millennium Pharmaceuticals Inc

Orum Therapeutics Inc

Paranta Biosciences Ltd

Pharma Mar SA

Philogen SpA

PTC Therapeutics Inc

QBiotics Group Ltd

Shanghai Junshi Bioscience Co Ltd

Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Fibrosarcoma - Overview

Fibrosarcoma - Therapeutics Development

Fibrosarcoma - Therapeutics Assessment

Fibrosarcoma - Companies Involved in Therapeutics Development

Fibrosarcoma - Drug Profiles

Fibrosarcoma - Dormant Projects

Fibrosarcoma - Discontinued Products

Fibrosarcoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Fibrosarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Fibrosarcoma – Pipeline by Advenchen Laboratories LLC, 2021

Fibrosarcoma – Pipeline by Alphamab Oncology, 2021

Fibrosarcoma – Pipeline by AntiCancer Inc, 2021

Fibrosarcoma – Pipeline by Apollomics Inc, 2021

Fibrosarcoma – Pipeline by AstraZeneca Plc, 2021

Fibrosarcoma – Pipeline by Bayer AG, 2021

Fibrosarcoma – Pipeline by BeiGene Ltd, 2021

Fibrosarcoma – Pipeline by Bicycle Therapeutics Plc, 2021

Fibrosarcoma – Pipeline by BioMed Valley Discoveries Inc, 2021

Fibrosarcoma – Pipeline by Cellestia Biotech AG, 2021

Fibrosarcoma – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Fibrosarcoma – Pipeline by Intezyne Inc, 2021

Fibrosarcoma – Pipeline by Lytix Biopharma AS, 2021

Fibrosarcoma – Pipeline by Mediolanum farmaceutici SpA, 2021

Fibrosarcoma – Pipeline by Millennium Pharmaceuticals Inc, 2021

Fibrosarcoma – Pipeline by Orum Therapeutics Inc, 2021

Fibrosarcoma – Pipeline by Paranta Biosciences Ltd, 2021

Fibrosarcoma – Pipeline by Pharma Mar SA, 2021

Fibrosarcoma – Pipeline by Philogen SpA, 2021

Fibrosarcoma – Pipeline by PTC Therapeutics Inc, 2021

Fibrosarcoma – Pipeline by QBiotics Group Ltd, 2021

Fibrosarcoma – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021

Fibrosarcoma – Pipeline by Y-mAbs Therapeutics Inc, 2021

Fibrosarcoma – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Fibrosarcoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports